Immunicum tillkännager avslutad Fas Ib och tidig stängning av ILIAD-studien Pressmeddelande 3 december 2021 Immunicum tillkännager avslutad Fas Ib och tidig stängning av ILIAD-studienImmunicum AB (“Immunicum”, publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på...

Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study Press Release  Stockholm, Sweden, December 3, 2021 Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study Immunicum AB (“Immunicum”, publ; IMMU.ST), a biopharmaceutical...

Immunicum tillkännager positiv granskning från Data Safety Monitoring Board av fas Ib IILIAD-studien Press Release 26 July 2021  Immunicum tillkännager positiv granskning från Data Safety Monitoring Board av fas Ib IILIAD-studien -- Independent Data Safety and Monitoring Board (DSMB) har avgivit...

Immunicum Announces Positive Review by Data Safety Monitoring Board for Phase Ib Part of ILIAD Study Press Release 26 July 2021 Immunicum Announces Positive Review by Data Safety Monitoring Board for Phase Ib Part of ILIAD Study  -- Independent Data Safety and Monitoring Board (DSMB) issues...